[go: up one dir, main page]

FI971669L - A cure for diseases caused by IL-6 production - Google Patents

A cure for diseases caused by IL-6 production Download PDF

Info

Publication number
FI971669L
FI971669L FI971669A FI971669A FI971669L FI 971669 L FI971669 L FI 971669L FI 971669 A FI971669 A FI 971669A FI 971669 A FI971669 A FI 971669A FI 971669 L FI971669 L FI 971669L
Authority
FI
Finland
Prior art keywords
cure
production
diseases caused
diseases
caused
Prior art date
Application number
FI971669A
Other languages
Finnish (fi)
Swedish (sv)
Other versions
FI971669A0 (en
FI121455B (en
Inventor
Tadamitsu Kishimoto
Asao Katsume
Hiroyuki Saito
Original Assignee
Chugai Pharmaceutical Co Ltd
Tadamitsu Kishimoto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=17300476&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI971669(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd, Tadamitsu Kishimoto filed Critical Chugai Pharmaceutical Co Ltd
Publication of FI971669A0 publication Critical patent/FI971669A0/en
Publication of FI971669L publication Critical patent/FI971669L/en
Application granted granted Critical
Publication of FI121455B publication Critical patent/FI121455B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Husbandry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
FI971669A 1994-10-21 1997-04-18 Pharmaceutical compositions for the treatment of diseases caused by IL-6 production FI121455B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP25701094 1994-10-21
JP25701094 1994-10-21
JP9502169 1995-10-20
PCT/JP1995/002169 WO1996012503A1 (en) 1994-10-21 1995-10-20 Remedy for diseases caused by il-6 production

Publications (3)

Publication Number Publication Date
FI971669A0 FI971669A0 (en) 1997-04-18
FI971669L true FI971669L (en) 1997-06-17
FI121455B FI121455B (en) 2010-11-30

Family

ID=17300476

Family Applications (3)

Application Number Title Priority Date Filing Date
FI971669A FI121455B (en) 1994-10-21 1997-04-18 Pharmaceutical compositions for the treatment of diseases caused by IL-6 production
FI20105844A FI122406B (en) 1994-10-21 2010-08-11 Pharmaceutical compositions for the treatment of diseases caused by IL-6 production, the disease being nephritis ie. nephritis
FI20115753A FI122970B (en) 1994-10-21 2011-07-15 Pharmaceutical compositions for the treatment of hyperimmunoglobulinemia caused by IL-6 production

Family Applications After (2)

Application Number Title Priority Date Filing Date
FI20105844A FI122406B (en) 1994-10-21 2010-08-11 Pharmaceutical compositions for the treatment of diseases caused by IL-6 production, the disease being nephritis ie. nephritis
FI20115753A FI122970B (en) 1994-10-21 2011-07-15 Pharmaceutical compositions for the treatment of hyperimmunoglobulinemia caused by IL-6 production

Country Status (12)

Country Link
US (1) US20070036785A1 (en)
EP (3) EP1884524A3 (en)
JP (1) JP4896093B2 (en)
CN (4) CN101829325A (en)
CA (1) CA2203182C (en)
CZ (3) CZ298325B6 (en)
FI (3) FI121455B (en)
HU (2) HU227708B1 (en)
NO (6) NO324046B1 (en)
PL (1) PL182089B1 (en)
RU (1) RU2147442C1 (en)
WO (1) WO1996012503A1 (en)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8017121B2 (en) 1994-06-30 2011-09-13 Chugai Seiyaku Kabushika Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
GB9702944D0 (en) * 1997-02-13 1997-04-02 Univ Manchester Reducing fibrosis
JPH10324639A (en) 1997-03-21 1998-12-08 Chugai Pharmaceut Co Ltd Preventing and therapeutic agent for disease associated with sensitized t cell containing il-6 antagonist as active ingredient
CN1824308A (en) * 1997-05-15 2006-08-30 中外制药株式会社 Therapeutic agent for cachexia
KR20090068385A (en) * 1997-08-15 2009-06-26 츄가이 세이야꾸 가부시키가이샤 Preventive and / or therapeutic agent for systemic lupus erythematosus containing anti- interleukin-6 receptor antibody as an active ingredient
JP4124573B2 (en) 1998-03-17 2008-07-23 中外製薬株式会社 A prophylactic or therapeutic agent for inflammatory bowel disease comprising an IL-6 antagonist as an active ingredient
CA2341239C (en) 1998-08-24 2011-01-04 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for pancreatitis comprising il-6 antagonist as an active ingredient
DE19948126A1 (en) * 1999-10-06 2001-04-12 Max Delbrueck Centrum Pharmaceutical agent for the treatment of cachexia and / or cardiogenic shock
EP1334731B1 (en) * 2000-10-25 2008-02-27 Chugai Seiyaku Kabushiki Kaisha Preventives or remedies for psoriasis containing as the active ingredient il-6 antagonist
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
PT2308888T (en) * 2001-11-14 2017-05-03 Janssen Biotech Inc Anti-il-6 antibodies, compositions, methods and uses
MXPA04007924A (en) * 2002-02-14 2005-05-17 Chugai Pharmaceutical Co Ltd Antibody-containing solution pharmaceuticals.
JP3738268B2 (en) 2003-02-24 2006-01-25 森永乳業株式会社 Interleukin-6 production inhibitor
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
CA2542691C (en) 2003-10-17 2013-09-24 Chugai Seiyaku Kabushiki Kaisha Il-6 antagonist for use as mesothelioma therapeutic agent
US8617550B2 (en) 2003-12-19 2013-12-31 Chugai Seiyaku Kabushiki Kaisha Treatment of vasculitis with IL-6 antagonist
EP1728801A4 (en) 2004-03-24 2009-10-21 Chugai Pharmaceutical Co Ltd Subtype of humanized antibody against interleukin-6 receptor
AR048335A1 (en) 2004-03-24 2006-04-19 Chugai Pharmaceutical Co Ltd THERAPEUTIC AGENTS FOR INTERNAL EAR DISORDERS CONTAINING AN IL-6 ANTAGONIST AS AN ACTIVE INGREDIENT
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
PT1899378E (en) * 2005-06-21 2010-01-26 Xoma Technology Ltd Il-1 beta binding antibodies and fragments thereof
JP5014143B2 (en) 2005-10-14 2012-08-29 学校法人福岡大学 Inhibitor of transplanted islet injury in islet transplantation
WO2007046489A1 (en) 2005-10-21 2007-04-26 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for heart disease
AR057582A1 (en) 2005-11-15 2007-12-05 Nat Hospital Organization AGENTS TO DELETE INDUCTION OF CYTOTOXIC T LYMPHOCYTES
WO2007086490A1 (en) 2006-01-27 2007-08-02 Keio University Remedy for disease associated with choroidal angiogenesis
CN105177091A (en) 2006-03-31 2015-12-23 中外制药株式会社 Antibody modification method for purifying bispecific antibody
CA2647846C (en) 2006-03-31 2016-06-21 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US9260516B2 (en) 2006-04-07 2016-02-16 Osaka University Method for promoting muscle regeneration by administering an antibody to the IL-6 receptor
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
PL2374818T3 (en) 2006-06-02 2013-05-31 Regeneron Pharma High affinity antibodies to human IL-6 receptor
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
CN101528778A (en) * 2006-08-18 2009-09-09 埃博灵克斯股份有限公司 Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signaling
MX2009007830A (en) 2007-01-23 2009-10-07 Univ Shinshu Chronic rejection inhibitor.
SI3187506T1 (en) 2007-05-21 2019-08-30 Alderbio Holdings Llc Antibodies to il-6 and use thereof
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8178101B2 (en) * 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
JP5859202B2 (en) * 2007-05-21 2016-02-10 アルダーバイオ・ホールディングズ・エルエルシー Novel rabbit antibody humanization method and humanized rabbit antibody
US20090238825A1 (en) * 2007-05-21 2009-09-24 Kovacevich Brian R Novel rabbit antibody humanization methods and humanized rabbit antibodies
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US20110245473A1 (en) 2007-09-26 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Anti-IL-6 Receptor Antibody
CN106519025B (en) 2007-09-26 2021-04-23 中外制药株式会社 Method for changing isoelectric point of antibody by using amino acid substitution of CDR
KR102339457B1 (en) 2007-09-26 2021-12-14 추가이 세이야쿠 가부시키가이샤 Modified antibody constant region
CA2708532C (en) * 2007-12-05 2018-06-05 Chugai Seiyaku Kabushiki Kaisha Anti-il31ra antibody and use thereof
PE20091174A1 (en) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd LIQUID FORMULATION WITH HIGH CONCENTRATION OF ANTIBODY CONTENT
CA2721052C (en) 2008-04-11 2023-02-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
ES2564635T3 (en) 2008-05-13 2016-03-28 Novimmune Sa Anti-IL-6 / IL-6R antibodies and methods of use thereof
CA2728243C (en) * 2008-06-05 2020-03-10 National Cancer Center Il-6 inhibitor for suppressing neuroinvasion in pancreatic cancer
TWI440469B (en) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
JO3672B1 (en) 2008-12-15 2020-08-27 Regeneron Pharma High Affinity Human Antibodies to PCSK9
KR101314880B1 (en) * 2009-03-19 2013-10-04 추가이 세이야쿠 가부시키가이샤 Rheumatoid arthritis treatment agent
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
WO2010107109A1 (en) 2009-03-19 2010-09-23 中外製薬株式会社 Antibody constant region variant
EP2417162A2 (en) 2009-04-10 2012-02-15 Ablynx N.V. Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
MX2011010681A (en) 2009-04-10 2012-01-20 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders.
RU2011151069A (en) 2009-05-15 2013-06-20 Чугаи Сейяку Кабусики Кайся ANTI-AXL ANTIBODY
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
DK2493922T3 (en) 2009-10-26 2017-04-24 Hoffmann La Roche Process for preparing a glycosylated immunoglobulin
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
EP2504030A4 (en) 2009-11-24 2013-06-26 Alderbio Holdings Llc Antagonists of il-6 to raise albumin and/or lower crp
JO3417B1 (en) 2010-01-08 2019-10-20 Regeneron Pharma Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies
TWI609698B (en) 2010-01-20 2018-01-01 Chugai Pharmaceutical Co Ltd Stabilized antibody-containing solution preparation
EP2543730B1 (en) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
EP2578233B1 (en) 2010-05-28 2017-04-26 National Cancer Center Therapeutic agent for pancreatic cancer
SI2578231T1 (en) * 2010-05-28 2023-01-31 Chugai Seiyaku Kabushiki Kaisha Antitumor t cell response enhancer
KR20220070586A (en) 2010-11-08 2022-05-31 제넨테크, 인크. Subcutaneously administered anti-il-6 receptor antibody
RU2620071C2 (en) 2010-11-17 2017-05-22 Чугаи Сеияку Кабушики Каиша Multispecific antigen-binding molecule with alternate function to blood coagulation factor viii function
EP2643018B1 (en) 2010-11-23 2020-10-14 AlderBio Holdings LLC Anti-il-6 antibodies for the treatment of oral mucositis
BR112013013354A2 (en) * 2010-11-30 2020-10-06 Chugai Seiyaku Kabushiki Kaisha antigen-binding molecule capable of binding to a plurality of antigen molecules repeatedly
MX347602B (en) 2011-01-28 2017-05-03 Sanofi Biotechnology Pharmaceutical compositions comprising human antibodies to pcsk9.
EP2679681B2 (en) 2011-02-25 2023-11-15 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIB-specific FC antibody
AR087305A1 (en) 2011-07-28 2014-03-12 Regeneron Pharma STABILIZED FORMULATIONS CONTAINING ANTI-PCSK9 ANTIBODIES, PREPARATION METHOD AND KIT
DK2747782T3 (en) 2011-09-23 2018-04-23 Ablynx Nv Long-term inhibition of interleukin-6-mediated signal transmission
JP6322411B2 (en) 2011-09-30 2018-05-09 中外製薬株式会社 Antigen-binding molecules that promote the disappearance of antigens with multiple physiological activities
TW201326209A (en) 2011-09-30 2013-07-01 Chugai Pharmaceutical Co Ltd Therapeutic antigen-binding molecule having an FcRn binding domain that promotes antigen clearance
TWI589299B (en) 2011-10-11 2017-07-01 再生元醫藥公司 Composition for treating rheumatoid arthritis and method of use thereof
PL2663575T3 (en) 2011-10-28 2015-03-31 Regeneron Pharma Humanized il-6 and il-6 receptor
JP6117915B2 (en) 2012-05-21 2017-04-19 コリア リサーチ インスティテュート オブ バイオサイエンス アンド バイオテクノロジーＫｏｒｅａ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｂｉｏｓｃｉｅｎｃｅ Ａｎｄ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Pharmaceutical composition for preventing or treating STAT3-mediated diseases, comprising an extract of Mizokouju or a fraction thereof as an active ingredient
WO2014042251A1 (en) * 2012-09-13 2014-03-20 中外製薬株式会社 Gene knock-in non-human animal
JP6442404B2 (en) 2013-06-11 2018-12-19 国立研究開発法人国立精神・神経医療研究センター Method for predicting treatment prognosis in patients with relapsing-remitting multiple sclerosis (RRMS), and method for determining new treatment indication
WO2015000865A1 (en) 2013-07-04 2015-01-08 F. Hoffmann-La Roche Ag Interference-suppressed immunoassay to detect anti-drug antibodies in serum samples
CN105764922B (en) 2013-09-27 2020-07-17 中外制药株式会社 Preparation method of polypeptide heteromultimer
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
MA40764A (en) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd THERAPEUTIC AGENT INDUCING CYTOTOXICITY
WO2016062766A1 (en) 2014-10-21 2016-04-28 Ablynx Nv Treatment of il-6r related diseases
MY181199A (en) 2014-12-19 2020-12-21 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
TWI617580B (en) 2014-12-19 2018-03-11 中外製藥股份有限公司 Anti-c5 antibodies and methods of use
CN107108729A (en) 2015-02-05 2017-08-29 中外制药株式会社 Antibody comprising ion concentration-dependent antigen-binding domain, FC region variant, IL-8-binding antibody, and application thereof
RU2730590C2 (en) 2015-02-27 2020-08-24 Чугаи Сейяку Кабусики Кайся Composition for treating diseases associated with il-6
WO2016159213A1 (en) 2015-04-01 2016-10-06 中外製薬株式会社 Method for producing polypeptide hetero-oligomer
ES2888801T3 (en) 2015-05-19 2022-01-07 Nat Center Neurology & Psychiatry Method to determine the application of a new therapy in patients with multiple sclerosis (MS)
US11174317B2 (en) 2015-06-04 2021-11-16 National Center Of Neurology And Psychiatry Therapeutic agent for mental illness comprising IL-6 inhibitor as active ingredient
US10772956B2 (en) 2015-08-18 2020-09-15 Regeneron Pharmaceuticals, Inc. Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab
US11001622B2 (en) * 2015-11-19 2021-05-11 The Brigham And Women's Hospital, Inc. Method of treating autoimmune disease with lymphocyte antigen CD5-like (CD5L) protein
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
CA3004288C (en) 2015-12-28 2025-05-27 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of fc region-containing polypeptide
US11484591B2 (en) 2016-02-22 2022-11-01 Ohio State Innovation Foundation Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin A analogues or metabolites, and estradiol metabolites
BR112018068363A2 (en) 2016-03-14 2019-01-15 Chugai Seiyaku Kabushiki Kaisha cell damage-inducing therapeutic drug for use in cancer therapy
TWI820000B (en) 2016-04-28 2023-11-01 日商中外製藥股份有限公司 Antibody-containing preparations
JP6527643B2 (en) 2016-08-05 2019-06-05 中外製薬株式会社 Composition for treating or preventing IL-8 related diseases
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
US11608374B2 (en) 2017-01-30 2023-03-21 Chugai Seiyaku Kabushiki Kaisha Anti-sclerostin antibodies and methods of use
AU2018234844B2 (en) 2017-03-17 2024-01-25 Ohio State Innovation Foundation Nanoparticles for delivery of chemopreventive agents
JP7185884B2 (en) 2017-05-02 2022-12-08 国立研究開発法人国立精神・神経医療研究センター METHOD FOR PREDICTING AND DETERMINING THERAPEUTIC EFFECT OF IL-6 AND NEUTROPHIL-RELATED DISEASE
WO2019078344A1 (en) 2017-10-20 2019-04-25 学校法人兵庫医科大学 Anti-il-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
AR113816A1 (en) 2017-11-01 2020-06-17 Chugai Pharmaceutical Co Ltd VARIANTS AND ISOFORMS OF ANTIBODIES WITH REDUCED BIOLOGICAL ACTIVITY
IL277375B2 (en) 2018-03-15 2025-08-01 Chugai Pharmaceutical Co Ltd Antibodies against dengue virus that cross-react with Zika virus and methods of using them
EP3917618A1 (en) 2019-01-31 2021-12-08 Sanofi Biotechnology Anti-il-6 receptor antibody for treating juvenile idiopathic arthritis
US20220177978A1 (en) 2019-04-02 2022-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
JP2022545312A (en) 2019-04-24 2022-10-27 サノフィ・バイオテクノロジー Methods of diagnosis and treatment of rheumatoid arthritis
MA56116A (en) 2019-06-04 2022-04-13 Stefano Fiore COMPOSITIONS AND METHODS FOR TREATING PAIN IN SUBJECTS WITH RHEUMATOID ARTHRITIS
CN117247451B (en) * 2023-11-17 2024-02-09 中国人民解放军军事科学院军事医学研究院 A single domain antibody against human interleukin-6 protein and its application

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670373A (en) * 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
US5171840A (en) 1988-01-22 1992-12-15 Tadamitsu Kishimoto Receptor protein for human B cell stimulatory factor-2
US5814307A (en) * 1989-04-10 1998-09-29 Bristol-Myers Squibb Company Method for regulating cell growth, leukocyte differentiation and tumor cell growth using Oncostatin M to stimulate synthesis of IL-6
US5216128A (en) * 1989-06-01 1993-06-01 Yeda Research And Development Co., Ltd. IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it
SG42954A1 (en) * 1989-07-20 1997-10-17 Tadamitsu Kishimoto Antibody to human interleukin-6 receptor
JPH03155795A (en) * 1989-11-13 1991-07-03 Chuzo Kishimoto Mouse-interleukin-6 receptor protein
DE3939706C1 (en) * 1989-12-01 1991-03-21 Centre Regional De Transfusion Sanguine, Besancon, Fr
JP3045172B2 (en) * 1990-05-19 2000-05-29 岸本 忠三 Chemical method for measuring human IL-6 using IL-6 receptor and kit therefor
JP3212597B2 (en) * 1990-08-01 2001-09-25 忠三 岸本 Human IL-6 receptor immunochemical assay and assay kit
DE4028487A1 (en) * 1990-09-09 1992-03-12 Peter Dr Med Wehling Interleukin inhibitors of cytokine synthesis - used to treat nerve inflammation, associated pain, spinal injury and slipped disc
JPH04187645A (en) * 1990-11-22 1992-07-06 Chuzo Kishimoto Agent for suppressing action of interleukin 6
JPH05227970A (en) * 1992-02-19 1993-09-07 Chugai Pharmaceut Co Ltd Reconstructed human antibody to human interleukin-6 receptor
TW205553B (en) * 1991-04-25 1993-05-11 Chugai Pharmaceutical Co Ltd
JP3258348B2 (en) * 1991-08-02 2002-02-18 東ソー株式会社 HIV infection inhibitor
FR2694767B1 (en) * 1992-08-13 1994-10-21 Innotherapie Lab Sa Anti-IL6R monoclonal antibodies, and their applications.
AU678399B2 (en) * 1992-08-21 1997-05-29 United States Of America, As Represented By The Secretary, Department Of Health And Human Services A novel B-lymphoma cell line and antigen
JP3525221B2 (en) * 1993-02-17 2004-05-10 味の素株式会社 Immunosuppressants
US5888510A (en) * 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
US5759546A (en) * 1994-02-04 1998-06-02 Weinberg; Andrew D. Treatment of CD4 T-cell mediated conditions
ES2264135T3 (en) * 1995-02-13 2006-12-16 Chugai Seiyaku Kabushiki Kaisha INHIBITOR OF THE DECOMPOSITION OF MUSCLE PROTEINS CONTAINING ANTIBODIES AGAINST THE IL-6 RECEIVER.
US20020187150A1 (en) * 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
JP4124573B2 (en) * 1998-03-17 2008-07-23 中外製薬株式会社 A prophylactic or therapeutic agent for inflammatory bowel disease comprising an IL-6 antagonist as an active ingredient
JP4889187B2 (en) * 2000-10-27 2012-03-07 中外製薬株式会社 A blood MMP-3 concentration reducing agent comprising an IL-6 antagonist as an active ingredient
UA80091C2 (en) * 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
MXPA04009243A (en) * 2002-04-12 2005-06-08 Pfizer Use of ep4 receptor ligands in the treatment of il-6 involved diseases.
GB2401040A (en) * 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases

Also Published As

Publication number Publication date
FI971669A0 (en) 1997-04-18
FI20115753L (en) 2011-07-15
HU227708B1 (en) 2011-12-28
CN1306963C (en) 2007-03-28
NO330582B1 (en) 2011-05-16
US20070036785A1 (en) 2007-02-15
EP1884524A3 (en) 2008-06-25
CZ298790B6 (en) 2008-01-30
EP0791359A4 (en) 2002-09-11
JP2008297315A (en) 2008-12-11
FI122406B (en) 2012-01-13
PL182089B1 (en) 2001-11-30
EP2319535A2 (en) 2011-05-11
CN101829325A (en) 2010-09-15
CZ298325B6 (en) 2007-08-29
NO20073429L (en) 1997-06-18
NO330588B1 (en) 2011-05-23
AU3709995A (en) 1996-05-15
NO20073432L (en) 1997-06-18
WO1996012503A1 (en) 1996-05-02
FI20105844L (en) 2010-08-11
HU225392B1 (en) 2006-11-28
CN100350973C (en) 2007-11-28
CA2203182C (en) 2009-11-24
NO331944B1 (en) 2012-05-07
NO20073430L (en) 1997-06-18
NO971816D0 (en) 1997-04-18
NO324046B1 (en) 2007-08-06
EP2319535A3 (en) 2011-08-31
CZ296979B6 (en) 2006-08-16
AU689657B2 (en) 1998-04-02
NO330615B1 (en) 2011-05-30
HUT77035A (en) 1998-03-02
RU2147442C1 (en) 2000-04-20
CN101011574A (en) 2007-08-08
FI121455B (en) 2010-11-30
CZ118997A3 (en) 1997-09-17
FI122970B (en) 2012-09-14
NO20073431L (en) 1997-06-18
NO330589B1 (en) 2011-05-23
CN101011574B (en) 2012-10-03
JP4896093B2 (en) 2012-03-14
PL319785A1 (en) 1997-08-18
CN1164194A (en) 1997-11-05
CN1535728A (en) 2004-10-13
NO20073427L (en) 1997-06-18
EP0791359A1 (en) 1997-08-27
HK1067062A1 (en) 2005-04-01
EP1884524A2 (en) 2008-02-06
NO971816L (en) 1997-06-18
HU0304064D0 (en) 2004-03-01
CA2203182A1 (en) 1996-05-02

Similar Documents

Publication Publication Date Title
FI971669L (en) A cure for diseases caused by IL-6 production
ID942B (en) A PROCESS FOR PRODUCING ALCOHOL
MX9200080A (en) METHOD FOR THE MANUFACTURE OF A CELLULOSE MOLD.
FI962570L (en) Commercial ethanol production process
FI971172L (en) Method for preparing dosage units by wet granulation
NO941822L (en) Well view for increased production
FI930552A7 (en) A new method for producing nucleotides
FI914187L (en) The method prepares a 1-methylcarbapenem derivative of formula /I/
FI905249A7 (en) Method for manufacturing shaped parts
FI911207L (en) Method for preparing a novel therapeutically useful retinoid
ID21998A (en) PROCESS FOR THE MAKING OF A CONTINUOUS ALKIL 5-FORMILVALERATE COMPOUND
FI950631L (en) Method for producing molded cellulose structures
ITMI911548A0 (en) PROCEDURE FOR MANUFACTURING A CAMSHAFT
FI973235A0 (en) A method for inhibiting the effects of IL-6
KR950702117A (en) A REMEDY FOR INFLAMMATORY INTESTINAL DISEASES
FI972694A7 (en) A new method for preparing sameridine
AU689657C (en) Remedy for diseases caused by IL-6 production
DE69122876D1 (en) Mold manufacturing
FI931805L (en) Mold for making concrete elements
FI915960A7 (en) Method for making a mold
KR970000701U (en) Mold for manufacturing ventless tires
FI902296A7 (en) Method for manufacturing a plastic filter
LV11317A (en) Biohumus production tolerance
KR970016411U (en) Pneumatic injectors for industrial molds
KR960028052U (en) Molding press for tofu manufacturing

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 121455

Country of ref document: FI

MM Patent lapsed